Congenica Receives CE Mark for Genomic Analysis Software

Link to Full Article Cambridge, United Kingdom – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC). With the In Vitro Diagnostic (IVD) designation, Congenica’s clinical decision support platform […]

Soterius selects MIP Diagnostics’ synthetic antibodies for rapid COVID-19 biosensor

Link to Full Article Soterius, an Australian medical device startup in the field of respiratory infection has selected MIP Diagnostics, a UK specialist in molecularly imprinted polymers for the affinity reagent in their novel COVID-19 biosensor. The Soterius biosensor utilizes MIP Diagnostics’ COVID-19 nanoMIP, which acts as a synthetic antibody to the SARS-CoV-2 spike protein. […]

GENINCODE ANNOUNCES MAJOR US COMMERCIALISATION PARTNERSHIP WITH EVERSANA

Link to Full Article GENinCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces its partnership with EVERSANA Life Sciences LLC (“EVERSANA”) as its launch and commercialisation partner to access the United States market for the GENinCode portfolio of polygenic cardiovascular disease (“CVD”) products focused on genetic risk. EVERSANA is a […]

ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER

Link to Full Article Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief Operating Officer. Lindsey brings a wealth of deep expertise and experience from the life science industry, with […]

ARECOR EXCLUSIVE FORMULATION STUDY COLLABORATION WITH PAR STERILE PRODUCTS TO DEVELOP A STABLE READY TO USE PRODUCT

Link to Full Article Cambridge, UK, 7th June 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has signed a formulation study agreement with Par Sterile Products, LLC, an Endo International plc company (“Par”). Under this agreement, Arecor will use its proprietary formulation technology […]

Destiny Pharma Result of Annual General Meeting

Link to Full Article Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed. The full text of each resolution was included […]

MIP Diagnostics’ COVID-19 nanoMIP offers significantly improved sensitivity to antibodies in a diagnostic sensor

Link to Full Article MIP Diagnostics Ltd. has today shared the news that its COVID-19 nanoMIP outperforms commercial antibodies in a sensor platform, which could enable improved detection of lower viral loads during a wider infection period. Following the launch of its COVID-19 nanoMIP in April 2021, the business has worked with external collaborators to […]

Congenica named in UK’s Digital Health Playbook – ‘First 100’ Companies

Link to Full Article Cambridge, United Kingdom – 27 May 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, has been featured in the UK’s Digital Health Playbook – ‘First 100’. An initiative  the Department of International Trade to highlight the nation’s most innovative and impactful digital health companies.    The First 100 list features UK businesses with a proven track record of benefiting […]

Destiny Pharma Notice to Register for 2021 AGM

Link to Full Article Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and […]

Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update

Link to Full Article Company earns $750,000 milestone payment related to SWARM-P.a. Study MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided […]